Study M1143
Study name | Wang YP 2023 |
Title | Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder |
Overall design | The aim of this study was to investigate the effects of escitalopram on gut microbiota and the relationship between gut microbiota and escitalopram efficacy in major depressive disorder (MDD). In this study, 110 MDD patients (MDD group) and 166 healthy individuals (control group) were recruited. MDD patients were then treated with escitalopram for a period of 12 weeks. The initial dose of escitalopram was set at 5 mg per day, and within a period of 7 days, it was gradually increased to a range of 10-20 mg per day. Once the optimal dose was determined, it remained stable for the duration of the 12-week trial. After treatment, 56 patients achieved remission (defined as remitters with HAMD-17 <= 7; remission group) and 54 patients (49.09%) remained in a non-remission state (defined as non-remitters with HAMD-17 > 7; non-remission group). A longitudinal multi-omics analysis of fecal and plasma samples was performed. |
Study Type | Type1; Type2; Type4; |
Data available | |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD |
Sample size | 276 |
Tissue | Peripheral; Blood; Plasma; Peripheral; Faece; Faece; |
Platform | MS-based; GC-MS: Agilent 7890A-5975C GC-MS platform (Agilent, USA); |
PMID | |
DOI | |
Citation | Wang Y, Zhou J, Ye J, et al. Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder. Microbiome. 2023 Aug 28;11(1):195. |
Metabolite | Linoleic acid; Oleic acid; Stearic acid; 3-Hydroxybutyric acid; Palmitic acid; L-Phenylalanine; L-Valine; L-Proline; L-Glutamic acid; L-Threonine; L-Methionine; L-Lactic acid; L-Alanine; L-Glutamine; Indole-3-propionic acid; L-Tyrosine; Chenodeoxycholic acid; 2-Hydroxybutyric acid; 5-Methoxytryptamine; L-Malic acid; |
